Market Overview

UPDATE: Tigress Initiates Coverage On Illumina

Share:
Related ILMN
Short Interest Surges In Illumina And Vertex Pharmaceuticals
Goldman Adds Agilent To Conviction List: 'EPS Drivers Are Underappreciated'

In a report released Friday, Tigress analyst Philip Van Deusen initiated coverage on Illumina (NASDAQ: ILMN) with a Buy rating.

Analysts at Tigress favor Illumina for reducing costs in its genomic health progress with its genetic testing, diagnosis and individualized treatment. Illumina's development of hardware will strengthen, influencing an increase to barriers to entry. Tigress holds high expectations for Illumina sequencing machines, growing 51 percent year over year and making a majority of the company's revenue.

Latest Ratings for ILMN

DateFirmActionFromTo
May 2016CitigroupMaintainsBuy
May 2016Morgan StanleyMaintainsEqual-weight
May 2016NomuraMaintainsBuy

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: Philip Van Deusen TigressInitiation Analyst Ratings

 

Related Articles (ILMN)

View Comments and Join the Discussion!